Concepedia

Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance

Andrew J Fratoni, John Mah, David P. Nicolau, Joseph L. Kuti

Journal of Antimicrobial Chemotherapy · 2022 · 16 citations · 26 references

DOI

Abstract

Despite enhanced clearance of both imipenem and relebactam, the currently approved dosing regimen for normal renal function was predicted to achieve optimal exposure in critically-ill patients with ARC sufficient to treat most susceptible pathogens.

References

26

Prevention of Resistance: A Goal for Dose Selection for Antimicrobial Agents

George L. Drusano · Clinical Infectious Diseases · 2003 · 358 citations

, , +18

Augmented Renal Clearance in the ICU

Andrew Udy, João Pedro Baptista, Noelle Lim et al. · Critical Care Medicine · 2013 · 267 citations

Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance

Ghady Haidar, Nathan J Philips, Ryan K. Shields et al. · Clinical Infectious Diseases · 2017 · 265 citations · Full text

Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study

Angela Huttner, Elodie von Dach, Adriana Renzoni et al. · International Journal of Antimicrobial Agents · 2015 · 215 citations

, , +12

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Ivan Titov, Richard G. Wunderink, Antoine Roquilly et al. · Clinical Infectious Diseases · 2020 · 213 citations · Full text